Research programme: hepatitis B vaccine - CaroGen Corporation

Drug Profile

Research programme: hepatitis B vaccine - CaroGen Corporation

Latest Information Update: 20 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CaroGen
  • Developer CaroGen; Yale University School of Medicine
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 19 Oct 2016 CaroGen plans to license the Hepatitis B virus immunotherapy programme to GP Fortune Investment Partners in China
  • 17 Aug 2015 Preclinical trials in Hepatitis B in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top